RG
SNDX icon

Redmile Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Redmile Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-250,830
Closed -$2.47M – 55
2016
Q2 		$2.47M Sell
250,830
-12,170
-5% -$167K 0.24% 46
2016
Q1 		$3.5M Buy
+263,000
New +$3.31M 0.36% 38

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Redmile Group's SNDX Position: Q3 2016 in Review

Redmile Group sold out of Syndax Pharmaceuticals (SNDX) in Q3 2016, closing a stake of 250,830 shares — an estimated $2.47M sold.

Redmile Group first reported a position in SNDX in Q1 2016 and held it in 2 quarters. The position peaked at $3.5M in Q1 2016. 45 funds tracked by Wall St. Rank hold SNDX as of Q3 2016.

  • Redmile Group reported no remaining Syndax Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Redmile Group sold 250,830 Syndax Pharmaceuticals shares in Q3 2016, an estimated $2.47M.
  • Redmile Group first reported a position in Syndax Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Redmile Group's Syndax Pharmaceuticals position peaked at $3.5M in Q1 2016.
  • 45 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2016.

Based on Redmile Group's 13F filing for Q3 2016, filed 15 Nov 2016.